CTFP Volume 12 Issue 7

A publication of the American Thyroid Association

Table of Contents


Welcome to another issue of Clinical Thyroidology for the Public. In this journal, we will bring to you the most up-to-date, cutting edge thyroid research. We also provide even faster updates of late-breaking thyroid news through Twitter at @thyroidfriends and on Facebook. Our goal is to provide patients with the tools to be the most informed thyroid patient in the waiting room. Also check out our friends in the Alliance for Thyroid Patient Education. The Alliance member groups consist of: the American Thyroid Association, Bite Me Cancer, the Graves’ Disease and Thyroid Foundation, the Light of Life Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Thyroid Cancer Canada, Thyroid Cancer Alliance and Thyroid Federation International.

The American Thyroid Association (ATA) extends its appreciation to all of the patients and their families that are part of the ATA community — our Friends of the ATA. It is for you that the ATA is dedicated to carrying out our mission of providing reliable thyroid information and resources, clinical practice guidelines for thyroid detection and treatments, resources for connecting you with other patients affected by thyroid conditions, and cutting edge thyroid research as we search for better diagnoses and treatment outcomes for thyroid disease and thyroid cancer.

July is Graves’ Disease Awareness Month.

We have 2 special articles in this issue. The first is a memorial of the life of Dr. Lewis E. Braverman, a giant in the field of Thyroidology who recently passed away. The second is a guest blog from Dr. Elizabeth Pearce on behalf of the Iodine Global Network.

In this issue, the studies ask the following questions:

  • Do thyroid antibodies predict relapse in patients with Graves’ disease?
  • Are side effects of antithyroid drugs more common in patients with amiodarone-induced thyrotoxicosis?
  • Should thyroidectomy be considered in some patients with Hashimoto’s thyroiditis?
  • Are NIFTP tumors really benign?

We welcome your feedback and suggestions. Let us know what you want to see in this publication. I hope you find these summaries interesting and informative.

Alan P. Farwell, MD, FACE